ArticleCommunications biology2026

CRISPR-Cas9 screening identifies ATOX1-driven cisplatin resistance mechanisms in liver cancer and evaluates targeted inhibitor efficacy.

Chujiao Hu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.